Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Gestational diabetes ups long-term risk of impaired glucose tolerance, type 2 diabetes

11 Mar 2020

In women with a history of gestational diabetes, type 2 diabetes and impairments in glucose tolerance are likely to develop in the long-term, reports a new study.

Researchers conducted a prospective nested case-cohort study that included 118 women (mean age, 50.3 years) who were followed for 8, 15 and 22 years. Oral glucose tolerance tests and insulin assays were performed during follow-up assessments. The risk of impaired glucose tolerance or type 2 diabetes was the main outcome.

Over a mean follow-up of 22.5 years, 20 cases of type 2 diabetes were detected, with an overall incidence rate of 16.9 percent. At all time points, median plasma glucose levels were significantly higher in women with a history of gestational diabetes mellitus (GDM; p=0.001) or gestational impaired glucose tolerance (GIGT; p<0.001) than their comparators with normal glucose tolerance.

This was confirmed by multiple logistic regression analysis. A history of GDM/GIGT was significantly predictive of the development of type 2 diabetes or abnormal glucose tolerance at follow-up (odds ratio [OR], 2.78, 95 percent confidence interval [CI], 1.18–6.55; p=0.02).

The researchers also assessed the effect of GDM on longitudinal changes in glucose tolerance. By 8 years after birth, 40.3 percent of women with GDM/GIGT history were dysglycaemic, as compared to only 17.7 percent of those who had normal glucose tolerance (p=0.001). The corresponding values at 15 years were 51.1 percent and 20.2 percent (p<0.001), and 52.6 percent and 30.0 percent (p=0.025) at 22 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.